share_log

Mainz Biomed Analyst Ratings

Mainz Biomed Analyst Ratings

美因茨生物醫學分析師評級
Benzinga ·  2023/09/14 09:04
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/14/2023 112.26% Cantor Fitzgerald → $9 Reiterates Overweight → Overweight
08/22/2023 112.26% Cantor Fitzgerald → $9 Reiterates Overweight → Overweight
08/18/2023 65.09% HC Wainwright & Co. $10 → $7 Reiterates Buy → Buy
06/01/2023 135.85% HC Wainwright & Co. → $10 Reiterates → Buy
05/18/2023 183.02% Cantor Fitzgerald $15 → $12 Maintains Overweight
04/27/2023 135.85% HC Wainwright & Co. $25 → $10 Maintains Buy
03/30/2023 489.62% HC Wainwright & Co. → $25 Reiterates → Buy
02/16/2023 489.62% HC Wainwright & Co. → $25 Reiterates → Buy
02/10/2023 159.43% JonesTrading → $11 Initiates Coverage On → Buy
10/25/2022 253.77% Cantor Fitzgerald → $15 Initiates Coverage On → Overweight
06/21/2022 489.62% HC Wainwright & Co. → $25 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
09/14/2023 112.26% 康託·菲茨傑拉德 →$9 重申 超重→超重
2023年08月22日 112.26% 康託·菲茨傑拉德 →$9 重申 超重→超重
2023年08月18日 65.09% HC Wainwright公司 $10→$7 重申 購買→購買
06/01/2023 135.85% HC Wainwright公司 →$10 重申 →購買
2023年05月18日 183.02% 康託·菲茨傑拉德 $15→$12 維護 超重
04/27/2023 135.85% HC Wainwright公司 $25→$10 維護
03/30/2023 489.62% HC Wainwright公司 →$25 重申 →購買
02/16/2023 489.62% HC Wainwright公司 →$25 重申 →購買
02/10/2023 159.43% Jones Trading →$11 開始承保 →購買
2022年10月25日 253.77% 康託·菲茨傑拉德 →$15 開始承保 →超重
2022年06月21日 489.62% HC Wainwright公司 →$25 開始承保 →購買

What is the target price for Mainz Biomed (MYNZ)?

美因茨生物科技公司(MYNZ)的目標價是多少?

The latest price target for Mainz Biomed (NASDAQ: MYNZ) was reported by Cantor Fitzgerald on September 14, 2023. The analyst firm set a price target for $9.00 expecting MYNZ to rise to within 12 months (a possible 112.26% upside). 10 analyst firms have reported ratings in the last year.

坎託·菲茨傑拉德於2023年9月14日報道了美因茨生物化工(納斯達克:MYNZ)的最新目標價。這家分析公司將目標價定為9美元,預計紐西蘭元將在12個月內上漲(可能上漲112.26%)。去年有10家分析公司公佈了評級。

What is the most recent analyst rating for Mainz Biomed (MYNZ)?

美因茨生物科技公司(MYNZ)的最新分析師評級是多少?

The latest analyst rating for Mainz Biomed (NASDAQ: MYNZ) was provided by Cantor Fitzgerald, and Mainz Biomed reiterated their overweight rating.

美因茨·比默德(納斯達克:MYNZ)的最新分析師評級由坎託·菲茨傑拉德提供,美因茨·比梅德重申其增持評級。

When is the next analyst rating going to be posted or updated for Mainz Biomed (MYNZ)?

美因茨生物科技公司(MYNZ)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mainz Biomed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mainz Biomed was filed on September 14, 2023 so you should expect the next rating to be made available sometime around September 14, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公開財務報表,與美因茨生物美孚的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。美因茨·比默德的上一次評級是在2023年9月14日提交的,所以你應該預計下一次評級將在2024年9月14日左右的某個時候公佈。

Is the Analyst Rating Mainz Biomed (MYNZ) correct?

分析師對美因茨-比默德(MYNZ)的評級正確嗎?

While ratings are subjective and will change, the latest Mainz Biomed (MYNZ) rating was a reiterated with a price target of $0.00 to $9.00. The current price Mainz Biomed (MYNZ) is trading at is $4.24, which is within the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但美因茨生物美孚(MYNZ)的最新評級被重申,目標價在0.00美元至9.00美元之間。美因茨-比奧梅德目前的股價為4.24美元,處於分析師的預測區間內。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論